August 31, 2017 07:21 AM EDT

Incyte's good week continues with an encouraging update on IDO1 star epacadostat

John Carroll

Editor & Founder

Incyte’s complete response rate for a mid-stage combo of its IDO1 drug epacadostat with checkpoint legend Keytruda took a hit in the latest data update …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Incyte's good week continues with an encouraging update on IDO1 star epacadostat

John Carroll

Editor & Founder

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Pfizer says it has at least $10B available for deals in 2025, with a focus on pipeline

New study will try to stop Alzheimer’s decades before it begins, using experimental Eli Lilly drug

Amgen announces hold on Phase 1 obesity candidate, pipeline cuts

We’re about to find out which RFK Jr. will show up at HHS

Astellas shakes up management despite impressive nine-month earnings

Illumina added to China's blacklist following Biosecure Act, tariffs

In­cyte's good week con­tin­ues with an en­cour­ag­ing up­date on IDO1 star epaca­do­stat

Editor & Founder

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Incyte's good week continues with an encouraging update on IDO1 star epacadostat